Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Cash & Equivalents (2021 - 2025)

Historic Cash & Equivalents for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to $21.1 million.

  • Verrica Pharmaceuticals' Cash & Equivalents fell 826.09% to $21.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.1 million, marking a year-over-year decrease of 826.09%. This contributed to the annual value of $46.3 million for FY2024, which is 3338.46% down from last year.
  • According to the latest figures from Q3 2025, Verrica Pharmaceuticals' Cash & Equivalents is $21.1 million, which was down 826.09% from $15.4 million recorded in Q2 2025.
  • Verrica Pharmaceuticals' Cash & Equivalents' 5-year high stood at $84.3 million during Q3 2023, with a 5-year trough of $15.4 million in Q2 2025.
  • Its 5-year average for Cash & Equivalents is $39.6 million, with a median of $34.3 million in 2022.
  • As far as peak fluctuations go, Verrica Pharmaceuticals' Cash & Equivalents surged by 15962.49% in 2023, and later tumbled by 7271.91% in 2024.
  • Verrica Pharmaceuticals' Cash & Equivalents (Quarter) stood at $15.8 million in 2021, then surged by 117.58% to $34.3 million in 2022, then soared by 102.92% to $69.5 million in 2023, then tumbled by 33.38% to $46.3 million in 2024, then tumbled by 54.46% to $21.1 million in 2025.
  • Its last three reported values are $21.1 million in Q3 2025, $15.4 million for Q2 2025, and $29.6 million during Q1 2025.